Patient Selection Criteria for Low-Dose Ketamine Therapy

Patient selection for low dose ketamine therapy should begin with a confirmed diagnosis, a review of prior treatment, a medical and psychiatric safety screen, and a realistic plan for monitoring and follow-up. For depression, the clearest evidence and regulatory pathway concern treatment-resistant depression, while other uses require indication-specific clinical judgment.

Ketamine is an anesthetic medicine that is also used in some supervised psychiatric and pain-care settings. Esketamine, marketed as Spravato, is a related nasal-spray medicine approved by the U.S. Food and Drug Administration for specific depressive-disorder indications when used with appropriate monitoring.

Who may be considered for ketamine treatment?

For depression, clinicians commonly consider ketamine-based treatment after an adequate evaluation of treatment-resistant depression. Treatment-resistant depression usually refers to major depressive disorder that has not improved sufficiently after at least two appropriate antidepressant treatment attempts, though the exact definition and documentation process can vary by clinician and payer.

The FDA-approved pathway for intranasal esketamine includes adults with treatment-resistant depression and, in certain circumstances, depressive symptoms associated with acute suicidal ideation or behavior. The product label requires administration in a certified healthcare setting with observation after dosing. See the FDA-approved Spravato prescribing information for current labeled uses, contraindications, and monitoring requirements.

Low-dose ketamine is also discussed in research and clinical practice for acute suicidal thinking and some chronic pain conditions. Those situations need a setting that matches the person’s acuity and medical risk. A person with active suicidal intent or a plan needs urgent assessment and crisis support, not an unsupervised treatment decision.

Confirm the diagnosis and prior treatment history

Selection starts with diagnostic clarity. A structured clinical assessment can help distinguish major depressive disorder from bipolar depression, substance-induced mood symptoms, medical causes of depression, and other conditions that may call for a different treatment plan.

Prior treatment records matter. A useful review documents medication names, doses, duration, adherence, response, side effects, psychotherapy history, and prior procedures when relevant. This helps the treating clinician judge whether standard options have been adequately tried and whether ketamine addresses an unmet need. Readers exploring next steps after unsuccessful treatment can also review treatment-resistant depression next steps.

Screen for medical safety concerns

Ketamine can temporarily raise blood pressure and heart rate and can cause dissociation, sedation, and perceptual changes. For that reason, clinicians should review cardiovascular history, current blood pressure control, medication interactions, liver or urinary symptoms, allergy history, and any condition that could make short-term blood pressure elevation more concerning.

Some findings may mean treatment should not proceed, while others may call for specialist input, a different setting, closer monitoring, or another treatment choice. The specific decision depends on the formulation, dose, indication, medical history, and current clinical status. The National Library of Medicine’s ketamine drug information describes important precautions and adverse effects.

Blood pressure monitoring should be part of the plan when clinically indicated. Our guide to cardiovascular monitoring with ketamine explains why a baseline assessment and follow-up checks may be important.

Assess psychiatric history and current symptoms

Current psychotic symptoms require careful evaluation before ketamine is considered because ketamine can produce transient changes in perception and thinking. A past psychotic episode, bipolar disorder, severe dissociation, or a complex trauma history does not automatically answer every treatment question, but it can change the risk-benefit discussion and monitoring plan.

Bipolar-spectrum screening is particularly important for people presenting with depression. The clinician should assess any history of mania or hypomania, family history, medication-related mood elevation, sleep changes, impulsivity, and current mood-stabilizing treatment. Published ketamine research in bipolar depression remains more limited than the evidence base for unipolar treatment-resistant depression.

Substance-use history also needs a direct, nonjudgmental review. Ketamine has misuse potential, so active substance-use concerns may require a more structured setting, coordination with addiction care, or a decision to use another approach. A history alone should be assessed in context rather than used as a substitute for an individualized evaluation.

Consider practical readiness before treatment begins

A clinically appropriate treatment is not automatically practical for every person. The care plan should account for appointment availability, the required observation period, transportation after treatment, work or caregiving responsibilities, cost, and access to follow-up care.

For example, esketamine is subject to a Risk Evaluation and Mitigation Strategy, or REMS. REMS is an FDA safety program that can require controlled dispensing, certified treatment sites, and monitoring steps for specific medicines. According to the FDA, Spravato must be administered under direct observation in a certified healthcare setting and patients must be monitored for at least two hours after administration.

People using other ketamine formats should still receive clear instructions about post-treatment activities, driving restrictions, medication use, and whom to contact for concerning symptoms. The expected duration of effects and the required treatment schedule are separate questions, covered in how long ketamine effects can last and how treatments may be spaced.

A practical decision framework

1. Define the treatment goal

The goal should be specific: reducing severe depressive symptoms, addressing an acute crisis in an appropriate clinical setting, improving function, or evaluating an indication supported by the treating team’s evidence review. A clear goal makes it easier to assess benefit and decide whether to continue.

2. Match the setting to the risk

Higher medical or psychiatric complexity may require more monitoring, coordination with specialists, or a hospital-based setting. Lower apparent complexity still requires a plan for vital signs, adverse effects, follow-up, and escalation if symptoms worsen.

3. Review alternatives and interactions

Ketamine should be considered alongside psychotherapy, medication optimization, neuromodulation, sleep and substance-use care, and other appropriate options. Medication review matters because some medicines and substances can affect safety, sedation, blood pressure, or response. See ketamine drug interactions for a patient-focused overview.

4. Use shared decision-making

The patient should understand what is known, what remains uncertain, and what participation requires. The American Psychiatric Association consensus statement on ketamine for mood disorders emphasizes careful patient selection, monitoring, and informed discussion of risks and benefits. The full statement is available through PubMed.

5. Reassess over time

Selection is not a one-time event. Clinicians should track symptoms, functioning, adverse effects, blood pressure when relevant, substance-use concerns, and whether the treatment goal is being met. If benefit is limited or risks increase, the plan may need adjustment.

What emerging biomarkers can and cannot do

Researchers are studying inflammatory markers, brain-network measures, and genetic variants as possible predictors of ketamine response. These findings are interesting, but they are not yet a standard substitute for a clinical assessment. A biomarker result should not be treated as proof that a person will or will not respond.

For a closer look at this developing research, read biomarkers and ketamine response. The useful takeaway today is that patient selection remains primarily clinical: diagnosis, severity, treatment history, safety, preferences, and access to appropriate care.